Acquiring Company
Telix Pharmaceuticals Limited
Acquired Company
ITM
MelbourneBiotechnologyBiotechnologyHealth CareMedicalDescription
Telix Pharmaceuticals has agreed to acquire ITM for USD 1.65 billion. The acquisition will include cash and shares, along with contingent payments tied to regulatory approvals. This strategic purchase aims to enhance Telix's operations in radiopharmaceuticals. Shareholders of Telix are expected to own a majority of the combined entity post-transaction.
Fundz sees it the moment Telix Pharmaceuticals Limited makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired ITM?
ITM was acquired by Telix Pharmaceuticals Limited, based in Melbourne. The deal was reported on October 5, 2026. Telix Pharmaceuticals Limited (ASX: TLX) is a leading pharmaceutical company specializing in advanced diagnostic and therapeutic radiopharmaceuticals. Telix Pharmaceuticals Limited is publicly traded (TLX) and operates in Biotechnology.
When did Telix Pharmaceuticals Limited acquire ITM?
Telix Pharmaceuticals Limited's acquisition of ITM was reported on October 5, 2026. Telix Pharmaceuticals has agreed to acquire ITM for USD 1.65 billion. The acquisition will include cash and shares, along with contingent payments tied to regulatory approvals. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does ITM do?
ITM is involved in the production of medical isotopes and provides solutions for targeted cancer treatment. The company focuses on developing therapies that utilize these isotopes to improve patient outcomes in oncology. It is privately held, operating in Biotechnology.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.